Matthias Preusser

Matthias Preusser is an expert in Oncology at Medical University of Vienna (Austria). As of October 2026, ScienceLeadR ranks Matthias Preusser in the top 1% of experts worldwide for Nervous System Neoplasms, Brain Neoplasms and Glioma. Matthias Preusser has authored 874 publications, the most recent in 2026, and is an investigator in 17 clinical trials, 9 of them ongoing. SLR score: 3,853 (community average: 125). How the SLR is computed.

Oncology

Subspecialties: Neurology - Nuclear Medicine

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on October 19, 2026

Expert Rankings

Top experts on the MeSH terms this expert works on

Short Biography

Leading clinical trials on brain tumors.

Organizations

Career arc: 2003 - 2027

Source: PubMed

Medical University of Vienna

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 874

Citations

Citations: 36 903 1st author: 80 Last author: 161 Unique author: 11

Main journals

Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title	Journal	Year	Citations
Systemic inflammation and patient-reported quality of life as combined prognosticators in patients with solid tumors. PMID 42892236 — quality of life, neoplasms	Eur J Cancer	2026	0
Biomarker-guided and systemic treatment strategies for meningioma. PMID 42858154 — brain neoplasms, drug development, pharmaceutical preparations, neoplasms, biomarkers, meningioma, therapeutics	Neuro Oncol	2026	0
Radiotherapy versus observation following surgical resection of WHO grade 2 atypical meningioma (ROAM/EORTC-1308): an international, multicentre, open-label, phase 3, randomised controlled trial. PMID 42790456 — radiotherapy, disease-free survival, radiotherapy, adjuvant, meningioma, therapeutics	Lancet Top journal	2026	3
Distinct changes in plasma protein profiles of cancer patients receiving immune checkpoint inhibitors versus chemotherapy: implications for thrombosis risk and adverse outcomes. PMID 42787640 — cells, research design, lung, blood coagulation, venous thrombosis, neoplasms, carcinoma, non-small-cell lung, drug therapy, immune checkpoint inhibitors, lung neoplasms, small cell lung carcinoma, head and neck neoplasms, therapeutics, thrombosis, globulins, plasma, chemotherapy	Res Pract Thromb Haemost	2026	0
Tumor regression grades in locally advanced gastroesophageal adenocarcinoma: associations with survival, pathological risk factors, and molecular biomarkers in a 19-year real-world cohort. PMID 42733479 — neoplasms, adenocarcinoma, biomarkers, neoadjuvant therapy, risk factors, therapeutics, esophageal neoplasms, stomach neoplasms	ESMO Gastrointest Oncol	2026	0

Clinical Studies 17

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 3 Study Chair: 1

By phase:

Phase 2 9

N/A 4

Phase 3 3

By status:

Recruiting 8

Completed 4

Unknown 2

Active not recruiting 1

Withdrawn 1

By type:

Interventional 13

Observational 3

By Monocentric/Multicentric:

monocentric 5

multicentric2to4 2

multicentric5to9 1

multicentricup10 8

Main Topics

Nervous System Diseases 8

Skin and Connective Tissue Diseases 3

Respiratory Tract Diseases 2

Ongoing Clinical Trials

9 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study	Phase	Status	Start
A Phase III Study of TLX101 Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients with Recurrent Glioblastoma 2025-521785-10-00 — injections, safety, lomustine, solutions, glioblastoma, therapeutics	Phase 3	Recruiting	2026
Amino Acid PET based Response Assessment in IDH mutant Gliomas (APPEAR) NCT07159607 — brain neoplasms, glioma, oxidoreductases, tomography, astrocytoma, amino acids, positron-emission tomography, isocitrate dehydrogenase, brain, neoplasms, therapeutics, oligodendroglioma	N/A	Recruiting	2025
Vorasidenib Maintenance for IDH Mutant Astrocytoma NCT06809322 — astrocytoma, maintenance, chemoradiotherapy, therapeutics	Phase 3	Recruiting	2026
Personalized Targeted Glioblastoma Therapies by ex Vivo Drug Screening NCT06512311 — brain neoplasms, pharmaceutical preparations, brain, neoplasms, drug evaluation, preclinical, glioblastoma, therapeutics	N/A	Recruiting	2024
Standardized Clinical Assessment of Patients With Leptomeningeal Metastasis NCT06417710 — meningeal neoplasms, neoplasms, neoplasm metastasis, meningeal carcinomatosis	N/A	Recruiting	2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS

Shopping Cart

System Maintenance Notice